Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes

During a 1-year compassionate use program, 156 patients with migraine self-administered a monthly dose of erenumab 140 mg with a subcutaneous autoinjector. Main inclusion criteria were: ≥ 4 migraine days/month and ≥two prior prophylactic treatment failures. The patients covered the migraine severity...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenen, Jean, Timmermans, Gregory, Nonis, Romain, Manise, Maïté, Fumal, Arnaud, Gérard, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703164/
https://www.ncbi.nlm.nih.gov/pubmed/34956071
http://dx.doi.org/10.3389/fneur.2021.805334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703164/
https://www.ncbi.nlm.nih.gov/pubmed/34956071
http://dx.doi.org/10.3389/fneur.2021.805334

Ejemplares similares